Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 149

1.

Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa.

Lawn SD, Little F, Bekker LG, Kaplan R, Campbel E, Orrell C, Wood R.

AIDS. 2009 Jan 28;23(3):335-42. doi: 10.1097/QAD.0b013e328321823f.

2.

Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa.

Lawn SD, Myer L, Edwards D, Bekker LG, Wood R.

AIDS. 2009 Aug 24;23(13):1717-25. doi: 10.1097/QAD.0b013e32832d3b6d.

4.

Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/microl is associated with improved treatment outcomes in South Africa.

Fox MP, Sanne IM, Conradie F, Zeinecker J, Orrell C, Ive P, Rassool M, Dehlinger M, van der Horst C, McIntyre J, Wood R.

AIDS. 2010 Aug 24;24(13):2041-50. doi: 10.1097/QAD.0b013e32833c703e.

5.

Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community.

Gupta A, Wood R, Kaplan R, Bekker LG, Lawn SD.

PLoS One. 2012;7(3):e34156. doi: 10.1371/journal.pone.0034156. Epub 2012 Mar 30.

6.
7.

Prevalent and incident tuberculosis are independent risk factors for mortality among patients accessing antiretroviral therapy in South Africa.

Gupta A, Wood R, Kaplan R, Bekker LG, Lawn SD.

PLoS One. 2013;8(2):e55824. doi: 10.1371/journal.pone.0055824. Epub 2013 Feb 13.

8.

Gender differences in survival among adult patients starting antiretroviral therapy in South Africa: a multicentre cohort study.

Cornell M, Schomaker M, Garone DB, Giddy J, Hoffmann CJ, Lessells R, Maskew M, Prozesky H, Wood R, Johnson LF, Egger M, Boulle A, Myer L; International Epidemiologic Databases to Evaluate AIDS Southern Africa Collaboration.

PLoS Med. 2012;9(9):e1001304. Epub 2012 Sep 4.

9.

The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy.

Kaufmann GR, Bloch M, Finlayson R, Zaunders J, Smith D, Cooper DA.

AIDS. 2002 Feb 15;16(3):359-67.

PMID:
11834947
10.

Initiating antiretroviral therapy when presenting with higher CD4 cell counts results in reduced loss to follow-up in a resource-limited setting.

Clouse K, Pettifor A, Maskew M, Bassett J, Van Rie A, Gay C, Behets F, Sanne I, Fox MP.

AIDS. 2013 Feb 20;27(4):645-50. doi: 10.1097/QAD.0b013e32835c12f9.

11.

Association of age with mortality and virological and immunological response to antiretroviral therapy in rural South African adults.

Mutevedzi PC, Lessells RJ, Rodger AJ, Newell ML.

PLoS One. 2011;6(7):e21795. doi: 10.1371/journal.pone.0021795. Epub 2011 Jul 1.

12.

Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata.

Palella FJ Jr, Deloria-Knoll M, Chmiel JS, Moorman AC, Wood KC, Greenberg AE, Holmberg SD; HIV Outpatient Study Investigators.

Ann Intern Med. 2003 Apr 15;138(8):620-6.

PMID:
12693883
14.

Clinical predictors of immune reconstitution following combination antiretroviral therapy in patients from the Australian HIV Observational Database.

Rajasuriar R, Gouillou M, Spelman T, Read T, Hoy J, Law M, Cameron PU, Petoumenos K, Lewin SR.

PLoS One. 2011;6(6):e20713. doi: 10.1371/journal.pone.0020713. Epub 2011 Jun 2.

15.

Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection.

Lok JJ, Bosch RJ, Benson CA, Collier AC, Robbins GK, Shafer RW, Hughes MD; ALLRT team.

AIDS. 2010 Jul 31;24(12):1867-76. doi: 10.1097/QAD.0b013e32833adbcf.

16.

Reducing mortality with cotrimoxazole preventive therapy at initiation of antiretroviral therapy in South Africa.

Hoffmann CJ, Fielding KL, Charalambous S, Innes C, Chaisson RE, Grant AD, Churchyard GJ.

AIDS. 2010 Jul 17;24(11):1709-16. doi: 10.1097/QAD.0b013e32833ac6bc.

17.

Antiretroviral treatment cohort analysis using time-updated CD4 counts: assessment of bias with different analytic methods.

Kranzer K, Lewis JJ, White RG, Glynn JR, Lawn SD, Middelkoop K, Bekker LG, Wood R.

PLoS One. 2011;6(11):e27763. doi: 10.1371/journal.pone.0027763. Epub 2011 Nov 17.

18.

Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy.

Huttner AC, Kaufmann GR, Battegay M, Weber R, Opravil M.

AIDS. 2007 May 11;21(8):939-46.

PMID:
17457087
19.

Mortality, AIDS-morbidity, and loss to follow-up by current CD4 cell count among HIV-1-infected adults receiving antiretroviral therapy in Africa and Asia: data from the ANRS 12222 collaboration.

Gabillard D, Lewden C, Ndoye I, Moh R, Segeral O, Tonwe-Gold B, Etard JF, Pagnaroat M, Fournier-Nicolle I, Eholié S, Konate I, Minga A, Mpoudi-Ngole E, Koulla-Shiro S, Zannou DM, Anglaret X, Laurent C; ANRS 12222 Morbidity Mortality Study Group.

J Acquir Immune Defic Syndr. 2013 Apr 15;62(5):555-61. doi: 10.1097/QAI.0b013e3182821821.

20.

Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America.

ART-LINC Collaboration of International Databases to Evaluate AIDS (IeDEA), Keiser O, Anastos K, Schechter M, Balestre E, Myer L, Boulle A, Bangsberg D, Touré H, Braitstein P, Sprinz E, Nash D, Hosseinipour M, Dabis F, May M, Brinkhof MW, Egger M.

Trop Med Int Health. 2008 Jul;13(7):870-9. doi: 10.1111/j.1365-3156.2008.02078.x. Epub 2008 Mar 27.

Items per page

Supplemental Content

Write to the Help Desk